<qa>  What is the primary objective of part 1?This study is being conducted in 2 parts with the primary objective of part 1 being to determine the maximum tolerated dose MTD of CAMPATH alemtuzumab, MABCAMPATH, CAMPATH administered intravenously IV once a week as treatment for relapsing or refractory non-Hodgkins lymphoma NHL. The primary objective of part 2 is to determine the overall response rate complete response, CRunconfirmed , plus partial response of weekly IV CAMPATH in the treatment of relapsing or refractory NHL. This is a Phase III study, open-label, multicenter study to evaluate the efficacy and safety of weekly IV CAMPATH as therapy for patients with relapsing or refractory non-Hodgkins lymphoma. 